Novartis

BASEL, December 8, 2006 - At the 8th annual symposium of the Novartis Foundation for Sustainable Development, international experts discussed the role of development cooperation in today's and tomorrow's world. While the morning was devoted to a critical assessment of...

Basel - Dr. Daniel Vasella, Chairman and CEO of Novartis, announced today that the Novartis Institute for Tropical Diseases (NITD) will initiate research on malaria - estimated to annually kill more than one million people worldwide and one of the top three killer dis...

Basel, Switzerland--Novartis announced today that it is on track to produce 100 million treatment courses of its anti-malarial Coartem (artemether/lumefantrine) in 2006 (up from 30 million in 2005), if orders are placed by malaria-endemic developing countries in a tim...

Basel, Switzerland - Five Novartis project team leaders from sites in Bangladesh, India, Ireland and the US were honored today with the Energy Excellence Awards for their exceptional contributions to improving energy efficiency and reducing carbon dioxide (CO2) emissi...

Basel - Private initiative can change the world. That was the joint message issued by well-known speakers from a wide range of backgrounds at the international 2005 Symposium of the Novartis Foundation for Sustainable Development in Basel/ Switzerland. The large audie...

All leprosy patients in the world will continue to benefit from free medicines under an agreement signed today by the World Health Organization (WHO) and the pharmaceutical company, Novartis AG. This extends the current agreement until the end of 2010 and is valued at...

Bagamoyo, Tanzania - International experts at a symposium sponsored by the Novartis Institute for Tropical Diseases (NITD) are meeting to review advances in research on tuberculosis (TB) therapies. The meeting is addressing goals and problems of TB control with focus ...